# Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects

> **NCT00954252** · PHASE1 · COMPLETED · sponsor: **CERESPIR** · enrollment: 84 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CHF 5074
- **DRUG:** placebo
- **DRUG:** CHF 5074
- **DRUG:** CHF 5074
- **DRUG:** CHF 5074
- **DRUG:** CHF 5074
- **DRUG:** CHF 5074

## Key facts

- **NCT ID:** NCT00954252
- **Lead sponsor:** CERESPIR
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954252, "Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00954252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*